INVA 8003
Alternative Names: INVA-8003Latest Information Update: 26 Jul 2021
Price :
$50 *
At a glance
- Originator InveniAI; PRISM BioLab
- Class Peptidomimetics; Small molecules
- Mechanism of Action PYCARD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders; Inflammation
Most Recent Events
- 26 Jul 2021 InveniAI anticipates that INVA 8003 will be IND ready by H1 of 2023 (InveniAI pipeline, July 2021)
- 20 Jul 2021 Preclinical trials in Inflammation in USA (unspecified route) prior to July 2021
- 20 Jul 2021 Preclinical trials in Gastrointestinal disorders in USA (unspecified route) prior to July 2021